Skip to main content

Table 2 Characteristics of included studies for neoadjuvant chemotherapy

From: Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis

Study Year No. of cases Classification of pathologic response Definition of pCR NACT regimens Surgery after NACT
Agarwal 2017 38 Miller-Payne Miller-Payne grade V CEF, CAF, CEF + DE, DE, DC + Herceptin, DEC Modified radical mastectomy or wide local excision
Atuegwu 2013 28 No residual invasive cancer in the breast or lymph nodes AC + taxol, Taxotere, Taxol + cisplatin ± everolimus, Trastuzumab +carboplatin + ixabepilone, Trastuzumab, and lapatinib NR
Belli 2011 51 Mandard’s TRG criteria TRG 1 FEC, AT, TAC, and TC ± carboplatinum or trastuzumab Surgery
Bufi 2014 225 Mandard’s TRG criteria TRG 1 Doxorubicin and cyclophosphamide, and taxanes-based regimens Breast-conserving and nipple sparing surgery; Surgical excision
Bufi 2015 225 Mandard’s TRG criteria TRG 1 Doxorubicin, taxane, and cyclophosphamide-based regimens Breast-conserving and nipple sparing surgery; Surgical excision
Che 2016 36 Miller-Payne Miller-Payne grade V Paclitaxel with epirubicin or paclitaxel with carboplatin Breast-conserving surgery with axillary nodal clearance or modified radical mastectomy.
Fangberget 2010 31 Absence of invasive cancer 5-fluoro-uracil, epirubicin and cyclophosphamide Surgery
Fujimoto 2013 56 Japanese Breast Cancer Society criteria Necrosis or disappearance of all tumor cells Adriamycin and cyclophosphamide, paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide, paclitaxel Lumpectomy or mastectomy
Li 2011 32 Absence of invasive cancer on breast tumor and lymph nodes Docetaxel and epirubicin Breast-conserving surgery or modified radical mastectomy
Li 2015 42   No invasive tumor in the breast DOX + Cyc + Tax, Cis/Tax±RAD001, Tra + Car, Tra/Car/Her, Tax Mastectomy or lumpectomy
Luo 2014 71 Miller-Payne Miller-Payne grade V NR NR
Mani 2013 28 No residual tumor in the breast or lymph nodes Adriamycin/cytoxan, taxol/trastuzumab; docetaxel, carboplatin, and trastuzumab; or lapatinib and trastuzumab Surgery
Park 2010 53 Absence of recognizable invasive tumor cells (DCIS may have been present) Docetaxel and doxorubicin with granulocyte colony–stimulating factor Modified radical mastectomy or breast-conserving surgery
Park 2011 34 No residual malignancy and no sign of cancer cells; no residual invasive cancer and DCIS present Doxorubicin and docetaxel; paclitaxel, gemcitabine and trastuzumab Modified radical mastectomy or breast-conserving surgery
Richard 2013 118 Chevalier-Sataloff classifications Chevalier class 1, Sataloff A Epirubicin and cyclophosphamide, docetaxel; epirubicin and cyclophosphamide, trastuzumab Mastectomy or breast-conservative surgery
Sharma 2009 56 No residual tumor CEF; PþE NR
Shin 2012 90 No residual tumor or absence of invasive cancer, but presence of DCIS Doxorubicin and cyclophosphamide; cyclophosphamide and docetaxel; adriamycin plus docetaxel; 5-fluorouracil, epirubicin and cyclophosphamide; trastuzumab plus paclitaxel Surgery
Weis 2015 33 No residual tumor in the breast or nodes Paclitaxel, carboplatin, and trastuzumab; doxorubicin and cyclophosphamide, paclitaxel; cisplatin and paclitaxel ± everolimus NR
Woodhams 2010 69 No residual disease or no invasive cancer or DCIS present Anthracycline and cyclophosphamide, paclitaxel Quadrantectomy or mastectomy
Xu 2017 174 No residual tumor in the breast or nodes Cyclophosphamide + epirubicin and tatotere NR
  1. Miller-Payne grade V, showed complete disappearance of malignant cells at the site of tumor with only vascular fibroelastotic stroma seen with macrophages; TRG 1, complete regression, absence of residual tumor cells; Chevalier class 1, disappearance of all tumors on either macroscopic or microscopic assessment; Sataloff A, total or near total therapeutic effect; CEF, cyclophosphamide epirubicin 5-Fluorouracil; CAF cyclophosphamide adriamycin 5-fluorouracil; DE, docetaxel epirubicin; DC, docetaxel cisplatin; DEC, docetaxel epirubicin cisplatin; FEC, fluorouracil + epirubicin + cyclophosphamide; AT, doxorubicin + taxanes; TAC, taxanes + doxorubicin + cyclophosphamide; TC, taxanes + cyclophosphamide; Dox, doxorubicin; Cyc, cyclophosphamide; Cis, cisplatin; PþE, paclitaxel and epirubicin; NR, not reported